New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3

11.10.25

Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE

Rahul Khurana, MD; and Arshad Khanani, MD, MA

11.06.25

AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease

Peter Kaiser, MD; and Michel Michaelides, MD

10.23.25

Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDR

Allen Ho, MD; and Charles Wykoff, MD, PhD

09.04.25

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

David Lally, MD; and Ehsan Rahimy, MD

08.21.25

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

John Kitchens, MD; Krishna Mukkamala, MD

06.12.25

Duke AVS Clips: PVR, DR, Imaging, and MTM

Jason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed

06.09.25

Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI

Lejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD

06.05.25

Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs

Avni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD

05.29.25

ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

Marion Munk, MD, PhD; and Diana Do, MD

05.22.25

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

12.05.24

AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's

Adrienne Scott, MD; and Dilraj Grewal, MD

11.14.24

AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA

Durga S. Borkar, MD, MMCi; and Alex Melamud, MD

11.07.24

AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD

Jeremiah Brown, MD, MS; and Eric Schneider, MD

10.31.24

AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement

Rahul Khurana, MD; and Paul Hahn, MD, PhD

10.09.24

Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR

Ted Leng, MD; and Michael Klufas, MD

09.05.24

ASRS ’24: C1q Inhibition and Metformin for AMD

Joel Pearlman, MD, PhD; and Dimitra Skondra, MD

08.22.24

ASRS ’24: PAVILION at 100 Weeks

Margaret Chang, MD

08.08.24

ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings

Katherine Talcott, MD; and Sunir Garg, MD

06.05.24

ARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depression

Justis Ehlers, MD; and Lisa Faia, MD

05.17.24

ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE

Philip Storey, MD; and Prof. Sobha Sivaprasad

12.14.23

AAO ’23: Downward Trends in Reimbursement and ChatGPT in the Retina Clinic

John Thompson, MD and Raymond Iezzi, MD

11.30.23

AAO ’23: Real-World Faricimab Patterns and Improving GA Assessments

Sophie Bakri, MD; and Karl Csaky, MD, PhD

11.22.23

New Retina Radio AAO Late-Breakers: PULSAR at 96 Weeks and Home OCT in Wet AMD

Jean-François Korobelnik, MD, PhD; and W. Lloyd Clark, MD

11.13.23

New Retina Radio AAO Late-Breakers: ALTITUDE and DIAMOND

Mark Barakat, MD; and And Hani Salehi-Had, MD

09.01.23

ASRS ’23: Pegcetacoplan Extension Study, and Comparison of Pegcetacoplan and Avacincaptad Pegol

Nathan C. Steinle, MD; and Paul Hahn, MD, PhD

08.11.23

ASRS ’23: Missed Injections for AMD/DME/RVO and Anatomic Response to Vabysmo in Wet AMD

Christina Y. Weng, MD, MBA; and Nikolas JS London, MD

05.18.23

New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3

Diana Do, MD; and Jennifer Lim, MD

05.11.23

New Retina Radio ARVO Coverage: Faricimab in Wet AMD: Real-world and Phase 3 Data

Durga Borkar, MD, MMCi and Varun Chaudhary, MD

12.09.22

AAO '22: Biosimilars’ Practice Implications and Year 2 of YOSEMITE/RHINE

George Williams, MD, and Caroline Baumal, MD

12.01.22

AAO '22 Late-Breaking Talks: Gene Therapies for GA and XLRP

Michel Michaelides, BSc, MB, BS MD(Res), FRCOphth; and Jeffrey Heier, MD

11.10.22

AAO '22: Biomarkers and AI in the OR

Joan Miller, MD; and Yannek Leiderman, MD, PhD

11.03.22

AAO '22 Late-Breaking Talks: Biosimilar Phase 3 Data and TRUCKEE Update

Anat Loewenstein, MD; and Ramanath Bhandari, MD

10.25.22

AAO '22: GATHER2 Study Results

Arshad Khanani, MD, MS

09.15.22

ASRS Meeting Coverage Day 3: DR Biomarkers and Gene Tx for Achromatopsia

Jennifer Lim, MD; and Lejla Vajzovic, MD

08.04.22

ASRS Meeting Coverage Day 2: Diabetic Eye Disease Updates

John Kitchens, MD; and Michael Allingham, MD, PhD

07.28.22

ASRS Meeting Coverage Day 1: TALON and TRUCKEE in Wet AMD

Carl Regillo, MD; and Carl Danzig, MD

06.09.22

ARVO Meeting Coverage Day 3: CANDELA and ARCHWAY Data

David Brown, MD and Robert Mittra, MD

06.02.22

ARVO Meeting Coverage Day 2: Pipeline Therapies in GA

Allen C. Ho, MD and Jared Nielsen, MD, MBA

05.26.22

ARVO Meeting Coverage Day 1: LIGHTSITE III and DERBY/OAKS at 18 Months

12.17.21

AAO 2021: Updates in Uveitis and Trauma

Glenn Jaffe, MD; and Nicole Koulisis, MD

12.03.21

PALADIN for DME and ROP Updates From the ICROP

Michael Singer, MD; and R.V. Paul Chan, MD, MSc, MBA

11.30.21

AAO 2021 Late Breakers: DAVIO and NORSE-2

David Boyer, MD; and Firas Rahhal, MD

11.23.21

AAO 2021: Protocol W and Monitoring for Wet AMD

Raj Maturi, MD; and Usha Chakravarthy, MD

11.19.21

AAO 2021 Late Breakers: GATHER1 and ALTISSIMO

David Lally, MD; and Veeral Sheth, MD

11.05.21

ASRS 2021 Coverage: The Pipeline for Wet AMD and GA

Mark Barakat, MD; and Nancy Holekamp, MD

10.29.21

ASRS 2021 Coverage: Losing GA Patients to Follow-up and DME Meta-analysis

Durga Borkar, MD; and M. Ali Khan, MD

10.22.21

ASRS 2021 Coverage: ARCHWAY and TENAYA/LUCERNE

Chirag Jhaveri, MD; and Karl Csaky, MD

06.04.21

ARVO 2021 Coverage: NGM621 and COOG2

David Eichenbaum, MD; and Amy Schefler, MD

05.28.21

ARVO 2021: GATHER1 Study and CME After RRD Surgery

Veeral Sheth, MD; and Matthew Starr, MD

05.21.21

ARVO 2021 Coverage: TENAYA/LUCERNE Results—and Is Fluid OK in Wet AMD?

Arshad Khanani, MD, MA; and David Lally, MD

03.12.21

Angiogenesis 2021: Wet AMD

John Kitchens, MD; Diana Do, MD; and Carl Regillo, MD

03.04.21

Angiogenesis 2021: Geographic Atrophy

John Kitchens, MD; Pravin Dugel, MD, and SriniVas Sadda, MD

01.25.21

Clinical Impacts From AAO 2020: Drs. Singh, Ehlers, and Gillies

Rishi Singh, MD; Justis Ehlers, MD; and Mark Gillies, MD, PhD

12.17.20

Clinical Impacts From AAO 2020: Drs. Singh, Do, and Heier

Rishi Singh, MD; Diana Do, MD; and Jeffrey Heier, MD

12.07.20

DRCR Retina Network Protocol AB at AAO

Andrew Antoszyk, MD

12.02.20

AAO Late Breaker: IRIS Registry Data on GA

Ehsan Rahimy, MD

11.30.20

Coding Changes for 2021 at AAO

Joy Woodke

11.25.20

AAO Late Breaker: Ang-2 Mediation in DME Therapy

Karl Csaky, MD, PhD

11.23.20

Retinal Arteriolar Macroaneurysm and Anti-VEGF Therapy at AAO

J. Fernando Arevalo, MD, PhD

11.20.20

AAO Late Breaker: KSI-301 in DME Therapy

Arshad M. Khanani, MD, MA

11.18.20

ARCHWAY at AAO

Nancy Holekamp, MD

08.31.20

jCell Therapy for Retinitis Pigmentosa and Phase 2B Data

Anthony Joseph, MD

08.21.20

Treat-and-Extend in the Real World

Michael Singer, MD

08.12.20

Opioid Prescribing Patterns Among Retina Specialists

Yoshi Yonekawa, MD

08.04.20

Continuous Dosing in LADDER

Dilsher Dhoot, MD

06.30.20

Faricimab in Phase 2 and 3

Carl Danzig, MD

New Retina Radio:

New Retina Radio Meeting Coverage

New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3

Other Podcast Episodes